First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.
Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners
Latest from Georgetown Lombardi Comprehensive Cancer Center
Advertisement
Advertisement
Trending on CURE
1
Body Image and Sexual Health Challenges After Breast Cancer
2
Breast Cancer Awareness Needs Action, Not Just Pink Ribbons
3
What Libtayo Means for High-Risk Cutaneous Squamous Cell Carcinoma
4
FDA Grants Fast Tract Designation to VT3989 for Mesothelioma
5
